Document Detail


Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.
MedLine Citation:
PMID:  11801553     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The purpose of this study was to measure total levels of tissue inhibitor of metalloproteinases (TIMP-1) by ELISA in plasma from blood donors, patients with inflammatory bowel disease (IBD), and patients with cancer and to correlate the results to patient diagnosis. EXPERIMENTAL DESIGN: Total TIMP-1 plasma levels were measured by ELISA in blood samples from two different blood donor populations from IBD patients, and preoperative samples from patients with primary colon cancer (CC), rectal cancer (RC), or breast cancer. RESULTS: There were no significant differences in plasma TIMP-1 levels between healthy donors and IBD or breast cancer patients, whereas patients with CC or RC had significantly elevated TIMP-1 levels. Total TIMP-1 levels identified patients with CC with a sensitivity of 63% at 98% specificity, patients with early CC (Dukes' A+B) with a sensitivity of 56% at 98% specificity, and patients with right-sided CC with a sensitivity of 72% at 98% specificity. Combining carcinoembryonic antigen and TIMP-1 measurements increased the sensitivities obtained from TIMP-1 measurements alone. CONCLUSIONS: TIMP-1 was significantly elevated in plasma from CC and RC patients, including those with early-stage disease. Sensitivity and specificity were both sufficiently high to consider TIMP-1 as a marker for the early identification of CC patients, in particular, those with right-sided CC.
Authors:
Mads N Holten-Andersen; Ib Jarle Christensen; Hans Jørgen Nielsen; Ross W Stephens; Vibeke Jensen; Ole Haagen Nielsen; Steen Sørensen; Jens Overgaard; Hans Lilja; Adrian Harris; Gillian Murphy; Nils Brünner
Related Documents :
11800143 - Clinical significance of markedly elevated serum creatine kinase levels in patients wit...
3179943 - The evaluation of ca 19-9 antigen level in the early detection of pancreatic cancer. a ...
12406943 - The value of clock drawing in identifying executive cognitive dysfunction in people wit...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  8     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-01-21     Completed Date:  2002-04-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  156-64     Citation Subset:  IM    
Affiliation:
The Finsen Laboratory, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark. mads@finsenlab.dk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Blood Donors
Breast Neoplasms / enzymology,  pathology
Colonic Neoplasms / enzymology*,  pathology
Female
Humans
Inflammatory Bowel Diseases / enzymology,  pathology
Male
Middle Aged
Rectal Neoplasms / enzymology*,  pathology
Reference Values
Reproducibility of Results
Sensitivity and Specificity
Tissue Inhibitor of Metalloproteinase-1 / blood*,  diagnostic use
Tumor Markers, Biological / blood*
Chemical
Reg. No./Substance:
0/Tissue Inhibitor of Metalloproteinase-1; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk...
Next Document:  p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma.